Survival outcomes for HER2-low breast cancer: Danish national data.

IF 2.7 3区医学 Q3 ONCOLOGY

Acta Oncologica Pub Date : 2024-11-14 DOI:10.2340/1651-226X.2024.41280

Michael Sode, Kåre Nielsen, Maj-Britt Jensen, Tobias Berg, Ann Knoop, Bent Ejlertsen, Anne-Vibeke Lænkholm

{"title":"Survival outcomes for HER2-low breast cancer: Danish national data.","authors":"Michael Sode, Kåre Nielsen, Maj-Britt Jensen, Tobias Berg, Ann Knoop, Bent Ejlertsen, Anne-Vibeke Lænkholm","doi":"10.2340/1651-226X.2024.41280","DOIUrl":null,"url":null,"abstract":"Background and purpose: We investigated the prognosis of breast cancer (BC) with low expression of human epidermal growth factor receptor 2 (HER2), as previous studies have found varying impacts on survival of HER2-low BC compared with HER2 0 BC (HER2 IHC score of 0). HER2-low is defined as a score of 1+ or 2+ in an immunohistochemical (IHC) assay without HER2 gene amplification.Materials and methods: Patients with HER2 0 or HER2-low BC from the national Danish Breast Cancer Group database were examined by multivariable survival analysis in a retrospective noninterventional investigation. Patients were grouped as either HER2 0 or HER2-low. The primary endpoint was time to recurrence (TR), and the secondary endpoints were overall survival (OS) and distant recurrence-free interval (DRFI).Results: 41,610 patients were included (12,981 with HER2 0 BC and 28,629 with HER2-low BC). HER2-low BC was associated with a lower risk of recurrence (hazard ratio [HR]: 0.92, p = 0.03). Regarding secondary endpoints, HER2-low disease was linked to improved overall OS (HR: 0.94, p = 0.02). No statistically significant effect of HER2-low was found for DRFI, along with no differential effect of HER2-low according to estrogen receptor (ER) status.Interpretation: HER2-low BC was found to show an improved HR for OS and DRFI compared with HER2 0 BC; however, further studies are need to establish whether it represents a separate biological entity.","PeriodicalId":7110,"journal":{"name":"Acta Oncologica","volume":"63 ","pages":"878-886"},"PeriodicalIF":2.7000,"publicationDate":"2024-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta Oncologica","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2340/1651-226X.2024.41280","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background and purpose: We investigated the prognosis of breast cancer (BC) with low expression of human epidermal growth factor receptor 2 (HER2), as previous studies have found varying impacts on survival of HER2-low BC compared with HER2 0 BC (HER2 IHC score of 0). HER2-low is defined as a score of 1+ or 2+ in an immunohistochemical (IHC) assay without HER2 gene amplification.

Materials and methods: Patients with HER2 0 or HER2-low BC from the national Danish Breast Cancer Group database were examined by multivariable survival analysis in a retrospective noninterventional investigation. Patients were grouped as either HER2 0 or HER2-low. The primary endpoint was time to recurrence (TR), and the secondary endpoints were overall survival (OS) and distant recurrence-free interval (DRFI).

Results: 41,610 patients were included (12,981 with HER2 0 BC and 28,629 with HER2-low BC). HER2-low BC was associated with a lower risk of recurrence (hazard ratio [HR]: 0.92, p = 0.03). Regarding secondary endpoints, HER2-low disease was linked to improved overall OS (HR: 0.94, p = 0.02). No statistically significant effect of HER2-low was found for DRFI, along with no differential effect of HER2-low according to estrogen receptor (ER) status.

Interpretation: HER2-low BC was found to show an improved HR for OS and DRFI compared with HER2 0 BC; however, further studies are need to establish whether it represents a separate biological entity.

查看原文本刊更多论文

HER2 低水平乳腺癌的生存结果：丹麦全国数据。

背景和目的：我们调查了人表皮生长因子受体 2（HER2）低表达乳腺癌（BC）的预后，因为之前的研究发现，与 HER2 0 BC（HER2 IHC 得分为 0）相比，HER2 低表达 BC 对生存期的影响各不相同。HER2低定义为免疫组化（IHC）检测得分1+或2+，且无HER2基因扩增：在一项回顾性非干预调查中，通过多变量生存分析对丹麦乳腺癌小组国家数据库中的 HER2 0 或 HER2 低的 BC 患者进行了研究。患者被分为HER2 0或HER2-low两组。主要终点是复发时间（TR），次要终点是总生存期（OS）和无远处复发间隔（DRFI）：结果：共纳入 41,610 例患者（12,981 例为 HER2 0 BC，28,629 例为 HER2 低 BC）。HER2低的BC与较低的复发风险相关（危险比[HR]：0.92，P = 0.03）。在次要终点方面，HER2低与总体OS改善有关（HR：0.94，P = 0.02）。HER2-low对DRFI没有统计学意义上的影响，HER2-low对雌激素受体（ER）状态也没有不同的影响：与HER2为0的BC相比，HER2低的BC在OS和DRFI方面显示出更好的HR；然而，还需要进一步的研究来确定它是否代表一个独立的生物学实体。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Acta Oncologica 医学-肿瘤学

CiteScore

4.30

自引率

3.20%

发文量

301

审稿时长

3 months

期刊介绍： Acta Oncologica is a journal for the clinical oncologist and accepts articles within all fields of clinical cancer research. Articles on tumour pathology, experimental oncology, radiobiology, cancer epidemiology and medical radio physics are also welcome, especially if they have a clinical aim or interest. Scientific articles on cancer nursing and psychological or social aspects of cancer are also welcomed. Extensive material may be published as Supplements, for which special conditions apply.